In this review, we provide a detailed description of the significance of the promising immune checkpoint LAG-3 in the tumor microenvironment, discuss its role on different types of lymphocytes and autoimmune disorders, highlight its interplay with other immune checkpoints, as well as outline the new advances targeting LAG-3 in cancer immunotherapy. This evidence concerns the gene LAG3 and cancer.